Syndax Pharmaceuticals (SNDX) Gross Profit (2024 - 2026)

Syndax Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at $53.0 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 176.76% year-over-year to $53.0 million in Q1 2026; TTM through Mar 2026 was $213.2 million, a 407.56% increase from a year earlier, with the FY2025 full-year figure at $165.4 million, up 623.65% from the prior year.
• Gross Profit retreated to $53.0 million in Q1 2026 per SNDX's latest filing, from $85.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $85.9 million in Q4 2025 and bottomed at $3.5 million in Q2 2024.
• The 3-year median for Gross Profit is $27.9 million (2025), against an average of $31.9 million.
• Across the five-year window, Gross Profit jumped 1153.92% in 2025 and soared 176.76% in 2026, its largest moves.
• Year by year, Gross Profit stood at $6.9 million in 2024, then soared by 1153.92% to $85.9 million in 2025, then plunged by 38.31% to $53.0 million in 2026.
• Per Business Quant, the three latest SNDX Gross Profit figures stand at $53.0 million (Q1 2026), $85.9 million (Q4 2025), and $37.6 million (Q3 2025).